{
    "id": 1207,
    "fullName": "NTRK3 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK3 mutant indicates an unspecified mutation in the NTRK3 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4916,
        "geneSymbol": "NTRK3",
        "terms": [
            "NTRK3",
            "gp145(trkC)",
            "GP145-TrkC",
            "TRKC"
        ]
    },
    "variant": "mutant",
    "createDate": "07/30/2014",
    "updateDate": "05/16/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17316,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LOXO-195 treatment resulted in an objective response rate of 45% (9/20) and stable disease in 30% (6/20) of adult and pediatric patients with advanced solid tumors harboring a NTRK mutation associated with resistance to TRK inhibitors in the context of NTRK fusions, who had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511).",
            "molecularProfile": {
                "id": 32497,
                "profileName": "NTRK3 fusion NTRK3 mut"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15362,
                    "pubMedId": null,
                    "title": "Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9845"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1231,
            "profileName": "NTRK3 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32497,
            "profileName": "NTRK3 fusion NTRK3 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}